27566564|t|Altered pH gradient at the plasma membrane of osteosarcoma cells is a key mechanism of drug resistance
27566564|a|Current therapy of osteosarcoma (OS), the most common primary bone malignancy, is based on a combination of surgery and chemotherapy. Multidrug resistance mediated by P-glycoprotein (P-gp) overexpression has been previously associated with treatment failure and progression of OS, although other mechanisms may also play a role. We considered the typical acidic extracellular pH (pHe) of sarcomas, and found that doxorubicin (DXR) cytotoxicity is reduced in P-gp negative OS cells cultured at pHe 6.5 compared to standard 7.4. Short-time (24-48 hours) exposure to low pHe significantly increased the number and acidity of lysosomes, and the combination of DXR with omeprazole, a proton pump inhibitor targeting lysosomal acidity, significantly enhanced DXR cytotoxicity. In OS xenografts, the combination treatment of DXR and omeprazole significantly reduced tumor volume and body weight loss. The impaired toxicity of DXR at low pHe was not associated with increased autophagy or lysosomal acidification, but rather, as shown by SNARF staining, with a reversal of the pH gradient at the plasma membrane (ΔpHcm), eventually leading to a reduced DXR intracellular accumulation. Finally, the reversal of ΔpHcm in OS cells promoted resistance not only to DXR, but also to cisplatin and methotrexate, and, to a lesser extent, to vincristine. Altogether, our findings show that, in OS cells, short-term acidosis induces resistance to different chemotherapeutic drugs by a reversal of ΔpHcm, suggesting that buffer therapies or regimens including proton pump inhibitors in combination to low concentrations of conventional anticancer agents may offer novel solutions to overcome drug resistance.
27566564	0	19	Altered pH gradient	T081	C1138565
27566564	27	42	plasma membrane	T026	C0007603
27566564	46	58	osteosarcoma	T191	C0029463
27566564	59	64	cells	T025	C0007634
27566564	74	83	mechanism	T169	C0441712
27566564	87	102	drug resistance	T038	C0013203
27566564	111	118	therapy	T061	C0087111
27566564	122	134	osteosarcoma	T191	C0029463
27566564	136	138	OS	T191	C0029463
27566564	157	180	primary bone malignancy	T191	C4282132
27566564	196	235	combination of surgery and chemotherapy	T061	C0920442
27566564	237	257	Multidrug resistance	T032	C0242640
27566564	270	284	P-glycoprotein	T116,T123	C0242643
27566564	286	290	P-gp	T116,T123	C0242643
27566564	292	306	overexpression	T045	C1514559
27566564	343	360	treatment failure	T033	C0162643
27566564	365	376	progression	T046	C0242656
27566564	380	382	OS	T191	C0029463
27566564	399	409	mechanisms	T169	C0441712
27566564	458	481	acidic extracellular pH	T081	C0020283
27566564	483	486	pHe	T081	C0020283
27566564	491	499	sarcomas	T191	C1261473
27566564	516	527	doxorubicin	T109,T195	C0013089
27566564	529	532	DXR	T109,T195	C0013089
27566564	534	546	cytotoxicity	T049	C0596402
27566564	550	557	reduced	T080	C0392756
27566564	561	565	P-gp	T028	C0376623
27566564	575	577	OS	T191	C0029463
27566564	578	592	cells cultured	T025	C0007635
27566564	596	599	pHe	T081	C0020283
27566564	630	640	Short-time	T079	C0443303
27566564	655	666	exposure to	T080	C0332157
27566564	671	674	pHe	T081	C0020283
27566564	675	698	significantly increased	T081	C1707919
27566564	714	721	acidity	T034	C0368606
27566564	725	734	lysosomes	T026	C0024369
27566564	744	755	combination	T080	C0205195
27566564	759	762	DXR	T109,T195	C0013089
27566564	768	778	omeprazole	T109,T121	C0028978
27566564	782	803	proton pump inhibitor	T121	C0358591
27566564	814	831	lysosomal acidity	T043	C1156062
27566564	833	855	significantly enhanced	T081	C1707919
27566564	856	859	DXR	T109,T195	C0013089
27566564	860	872	cytotoxicity	T049	C0596402
27566564	877	879	OS	T191	C0029463
27566564	880	890	xenografts	T122	C0522537
27566564	896	917	combination treatment	T061	C0013218
27566564	921	924	DXR	T109,T195	C0013089
27566564	929	939	omeprazole	T109,T121	C0028978
27566564	940	961	significantly reduced	T038	C3890174
27566564	962	974	tumor volume	T081	C0475276
27566564	979	995	body weight loss	T033	C1262477
27566564	1001	1018	impaired toxicity	T037	C0013221
27566564	1022	1025	DXR	T109,T195	C0013089
27566564	1033	1036	pHe	T081	C0020283
27566564	1061	1070	increased	T081	C0205217
27566564	1071	1080	autophagy	T043	C0004391
27566564	1084	1107	lysosomal acidification	T043	C1156062
27566564	1133	1138	SNARF	T130	C0084578
27566564	1139	1147	staining	T059	C0487602
27566564	1156	1164	reversal	T169	C0443290
27566564	1172	1183	pH gradient	T081	C1138565
27566564	1191	1206	plasma membrane	T026	C0007603
27566564	1208	1213	ΔpHcm	T081	C1138565
27566564	1240	1247	reduced	T080	C0392756
27566564	1248	1251	DXR	T109,T195	C0013089
27566564	1252	1265	intracellular	T082	C0178719
27566564	1266	1278	accumulation	T033	C4055506
27566564	1293	1301	reversal	T169	C0443290
27566564	1305	1310	ΔpHcm	T081	C1138565
27566564	1314	1316	OS	T191	C0029463
27566564	1317	1322	cells	T025	C0007634
27566564	1332	1342	resistance	T169	C4281815
27566564	1355	1358	DXR	T109,T195	C0013089
27566564	1372	1381	cisplatin	T121,T197	C0008838
27566564	1386	1398	methotrexate	T109,T121	C0025677
27566564	1428	1439	vincristine	T109,T121	C0042679
27566564	1480	1482	OS	T191	C0029463
27566564	1483	1488	cells	T025	C0007634
27566564	1490	1500	short-term	T079	C0443303
27566564	1501	1509	acidosis	T046	C0001122
27566564	1518	1528	resistance	T169	C4281815
27566564	1542	1564	chemotherapeutic drugs	T109,T121	C0003392
27566564	1570	1578	reversal	T169	C0443290
27566564	1582	1587	ΔpHcm	T081	C1138565
27566564	1605	1611	buffer	T121,T130	C0006353
27566564	1612	1621	therapies	T061	C0087111
27566564	1625	1633	regimens	T170	C2945654
27566564	1644	1666	proton pump inhibitors	T121	C0358591
27566564	1670	1681	combination	T080	C0205195
27566564	1689	1703	concentrations	T081	C1446561
27566564	1720	1737	anticancer agents	T109,T121	C0003392
27566564	1748	1753	novel	T080	C0205314
27566564	1767	1775	overcome	T052	C2983310
27566564	1776	1791	drug resistance	T038	C0013203